arrow
M

Mustafa Alperen Tunç

department of medical oncology
H指数:2
被引数:21

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

基线和早期治疗中的预后营养指数在激素受体阳性、HER2阴性转移性乳腺癌患者中的应用(接受CDK4/6抑制剂治疗)

2026-09-020
OA
Digital health engagement and health literacy among cancer patients: a cross-sectional study of ICT usage patterns

癌症患者数字健康参与度和健康素养:一项关于ICT使用模式的横断面研究

2026-08-210
OAAI
Stage-Specific Prognostic Impact of Longitudinal Body Composition Changes in Patients with Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX: A Dual-Cohort Study

胰腺导管腺癌患者纵向体成分变化在FOLFIRINOX治疗中的分期特异性预后影响:一项双队列研究

2026-08-140
OA
Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies

II期结肠癌的长期结局与条件无复发生存率:监测和复发检测策略的影响

2026-06-240
OA
Development and internal validation of the CLIP-M score for advanced mucosal malignant melanoma: exploratory prognostic stratification and comparative assessment with the RMH score

CLIP-M评分在进展期黏膜黑色素瘤中的开发与内部验证:探索性预后分层及与RMH评分的比较评估

2026-05-220
OAAI
Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
2026-01-260
OAAI
Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab

接受尼鲁单抗治疗转移性非小细胞肺癌患者治疗相关体成分变化的预后价值

2026-01-020
OAAI
Management of hepatotoxicity associated with CDK4/6 inhibitors and rechallenge strategies in metastatic hormone-positive, HER2-negative breast cancer

CDK4/6抑制剂相关肝毒性的管理及在转移性激素受体阳性、HER2阴性乳腺癌中的再挑战策略

2025-09-270
OA
Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group
2025-03-170
OAAI
Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors
2025-02-070
OAAI